益佰製藥(600594.SH):艾迪注射液擬中選廣東聯盟清開靈等中成藥集中帶量採購
格隆匯4月10日丨益佰製藥(600594.SH)公佈,近日,公司參加了廣東聯盟清開靈等中成藥集中帶量採購的投標。根據廣東省藥品交易中心2022年4月8日發佈的《廣東聯盟清開靈等中成藥集中帶量採購擬中選/備選結果公示表》,公司的產品艾迪注射液擬中選此次集中採購。
此次擬中選產品如確認中選,此次集中帶量採購聯盟地區的醫療機構將優先使用此次藥品集中採購中選產品,並確保完成約定採購量。此次公司的產品艾迪注射液擬中選價格與原基準價格相比下降幅度為13%,若公司後續簽訂購銷協議並實施,將有利於進一步擴大中選產品的銷售範圍,提高中選產品的市場佔有率,提升公司的品牌影響力,對公司長遠發展產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.